Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.480
-0.280 (-5.88%)
At close: Jan 28, 2026, 4:00 PM EST
4.480
0.00 (0.00%)
After-hours: Jan 28, 2026, 4:00 PM EST
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $6.31M in the twelve months ending September 30, 2025, down -36.36% year-over-year. In the year 2024, Taysha Gene Therapies had annual revenue of $8.33M, down -46.07%.
Revenue (ttm)
$6.31M
Revenue Growth
-36.36%
P/S Ratio
224.41
Revenue / Employee
$86,438
Employees
73
Market Cap
1.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 266.14M |
| AnaptysBio | 169.47M |
| Day One Biopharmaceuticals | 133.67M |
| Immatics | 99.45M |
| EyePoint | 42.34M |
| Inventiva | 19.93M |
| Capricor Therapeutics | 11.13M |
| DBV Technologies | 5.50M |
TSHA News
- 6 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 22 days ago - Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewsWire
- 7 weeks ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire
- 3 months ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire